Form 8-K - Current report:
SEC Accession No. 0001193125-26-253604
Filing Date
2026-06-02
Accepted
2026-06-02 16:30:16
Documents
9
Period of Report
2026-05-27
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kytx-20260527.htm   iXBRL 8-K 66209
  Complete submission text file 0001193125-26-253604.txt   172858

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kytx-20260527.xsd EX-101.SCH 24834
12 EXTRACTED XBRL INSTANCE DOCUMENT kytx-20260527_htm.xml XML 4717
Mailing Address 5980 HORTON STREET SUITE 200 EMERYVILLE CA
Business Address 5980 HORTON STREET SUITE 200 EMERYVILLE CA 5109252492
Kyverna Therapeutics, Inc. (Filer) CIK: 0001994702 (see all company filings)

EIN.: 831365441 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41947 | Film No.: 261056541
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)